Patents Assigned to Ablynx N.V.
  • Method for the production of immunoglobulin single variable domains
    Patent number: 10975141
    Abstract: Methods are provided for the manufacture of polypeptides comprising at least one immunoglobulin variable domain that result in an increased yield. The methods are based on simultaneous enhancement of one or more auxiliary proteins in the host.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: April 13, 2021
    Assignee: Ablynx N.V.
    Inventors: Peter Schotte, Manu De Groeve
  • Polypeptides against IL-23
    Patent number: 10968271
    Abstract: The present invention relates to amino acid sequences that are directed against Interleukin-23 (IL-23). The amino acid sequences of the present invention comprise two NANOBODIES® against IL-23 and one NANOBODY® against serum albumin, linked by two linkers (9GS linkers). In particular, the invention relates to the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 3 (listed in Table 1 and FIG. 1) (also referred to herein as “anti-IL 23 polypeptides of the invention”).
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: April 6, 2021
    Assignee: Ablynx N.V.
    Inventor: Marie-Ange Buyse
  • IMMUNOGLOBULIN VARIABLE DOMAINS
    Publication number: 20210087261
    Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).
    Type: Application
    Filed: December 9, 2020
    Publication date: March 25, 2021
    Applicant: Ablynx N.V.
    Inventors: Marie-Ange Buyse, Carlo Boutton
  • T cell recruiting polypeptides based on TCR alpha/beta reactivity
    Patent number: 10927186
    Abstract: T cell recruiting polypeptides are provided that bind the constant domain of TCR on a T cell. The polypeptides can be used in methods for treatment of cancers.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: February 23, 2021
    Assignee: Ablynx N.V.
    Inventors: Annelies Roobrouck, Diane Van Hoorick, João Vieira
  • METHOD FOR THE PRODUCTION OF IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
    Publication number: 20210047392
    Abstract: Methods are provided for the manufacture of polypeptides comprising at least one immunoglobulin variable domain that result in an increased yield. The methods are based on simultaneous enhancement of one or more auxiliary proteins in the host.
    Type: Application
    Filed: July 30, 2020
    Publication date: February 18, 2021
    Applicant: Ablynx N.V.
    Inventors: Peter Schotte, Manu De Groeve
  • Antigen binding dimer-complexes, methods of making/avoiding and uses thereof
    Patent number: 10919954
    Abstract: In a broad aspect the present invention generally relates to novel dimer-complexes (herein called “non-fused-dimers” or NFDs) comprising single variable domains, methods of making these complexes and uses thereof. These non-covalently bound dimer-complexes consist of two identical monomers that each comprises of one or more single variable domains (homodimers) or of two different monomers that each comprises on or more single variable domains (heterodimers). The subject NFDs have typically altered e.g. improved binding characteristics over their monomeric counterpart. The NFDs of the invention may further be engineered through linkage by a flexible peptide or cysteines in order to improve the stability. This invention also describes conditions under which such NFDs are formed and conditions under which the formation of such dimers can be avoided.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: February 16, 2021
    Assignee: Ablynx N.V.
    Inventors: Ann Brige, Christine Labeur, Marc Jozef Lauwereys
  • Methods of treating TTP with immunoglobulin single variable domains and uses thereof
    Patent number: 10919980
    Abstract: The present invention is based on the finding that administration of polypeptides comprising at least one Immunoglobulin single variable domains against vWF to human TTP patients provides a significant decrease in the time to response. The invention provides a polypeptide comprising at least one immunoglobulin single variable domain (ISVD) against von Willebrand Factor (vWF) for use in treating a vWF-related disease in a human in need thereof. The invention further relates to dosage unit forms, kits and medical uses for treating TTP.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: February 16, 2021
    Assignee: Ablynx N.V.
    Inventor: Christian Duby
  • P2X7 receptor binders and polypeptides comprising the same
    Patent number: 10875918
    Abstract: The present invention relates to amino acid sequences and polypeptides binding to the P2X7 receptor. In particular, the present invention relates to improved heavy-chain immunoglobulin single variable domains (also referred to herein as “ISV's” or “ISVD's”) binding to the P2X7 receptor, as well as to proteins, polypeptides and other constructs, compounds, molecules or 5 chemical entities that comprise such ISVD's.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: December 29, 2020
    Assignee: Ablynx N.V.
    Inventors: Marie-Ange Buyse, Catelijne Stortelers
  • METHOD FOR THE PRODUCTION OF IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
    Publication number: 20200392214
    Abstract: The present invention relates to an improved method for the manufacture of immunoglobulin single variable domains. More specifically, the present invention relates to a method of producing immunoglobulin single variable domains in which the proportion of carbamylated variants is strongly reduced or absent and to improved immunoglobulin single variable domains obtainable by methods of the present invention.
    Type: Application
    Filed: August 2, 2019
    Publication date: December 17, 2020
    Applicant: Ablynx N.V.
    Inventors: Ann Brige, Bart Walcarius, Yves Meyvis, Mauro Sergi
  • NUCLEOTIDE SEQUENCES ENCODING PEPTIDE LINKERS
    Publication number: 20200392512
    Abstract: The invention provides improved nucleotide sequences and nucleic acids that encode glycine serine linkers and that use an excess of GGA, GGG, and GGT/GGU codons to encode the glycine residues. The invention further relates to nucleotide sequences and nucleic acids that encode (fusion) proteins and polypeptides comprising glycine serine linkers, which nucleotide sequences and nucleic acids comprise such improved nucleotide sequences and nucleic acids of the invention.
    Type: Application
    Filed: February 26, 2019
    Publication date: December 17, 2020
    Applicant: Ablynx N.V.
    Inventors: Veronique De Brabandere, Ann Brige, Patrick Stanssens, Pieter-Jan De Bock, Tom Merchiers, Antonin De Fougerolles
  • Methods of treating TTP with immunoglobulin single variable domains and uses thereof
    Patent number: 10858445
    Abstract: The present invention is based on the finding that administration of polypeptides comprising at least one Immunoglobulin single variable domains against vWF to human TTP patients provides a significant decrease in the time to response. The invention provides a polypeptide comprising at least one immunoglobulin single variable domain (ISVD) against von Willebrand Factor (vWF) for use in treating a vWF-related disease in a human in need thereof. The invention further relates to dosage unit forms, kits and medical uses for treating TTP.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: December 8, 2020
    Assignee: Ablynx N.V.
    Inventor: Christian Duby
  • Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
    Patent number: 10858418
    Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: December 8, 2020
    Assignee: Ablynx N.V.
    Inventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Neotere Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
  • Amino acid sequences that modulate the interaction between cells of the immune system
    Patent number: 10844123
    Abstract: The present invention relates to amino acid sequences that block the interaction between (a target on) an antigen presenting cell (APC) and (a target on) a T-cell. More particularly, the present invention relates to amino acid sequences that are directed against (as defined herein) a target on an APC (also referred to herein as “APC target”) or a target on a T-cell (also referred to herein as “T-cell target”). The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: November 24, 2020
    Assignee: Ablynx N.V.
    Inventors: Guy Hermans, Peter Verheesen, Edward Dolk, Hendricus Renerus Jacobus Mattheus Hoogenboom, Michael John Scott Saunders, Hans De Haard, Renee de Bruin
  • Single variable domain antibodies against OX40L, constructs and therapeutic use
    Patent number: 10822425
    Abstract: The present invention relates to immunoglobulin single variable domain sequences that are directed against (as defined herein) OX40L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such immunoglobulin single variable domain sequences. In particular these immunoglobulin single variable domain sequences can block binding of OX40L to OX40. The immunoglobulin single variable domains, compounds and constructs can be used for prophylactic, therapeutic or diagnostic purposes, such as for the treatment of inflammatory disease and/or disorder such as e.g. asthma, allergic asthma, chronic colitis, Crohn's disease, inflammatory bowel disease, and/or arthrosclerosis.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: November 3, 2020
    Assignee: Ablynx N.V.
    Inventors: Frank Verdonck, Sigrid Cornelis, Stephanie Staelens
  • TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
    Publication number: 20200325221
    Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).
    Type: Application
    Filed: March 19, 2020
    Publication date: October 15, 2020
    Applicant: Ablynx N.V.
    Inventors: Judith Baumeister, Marie-Paule Lucienne Amanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Neotere Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
  • IMPROVED SERUM ALBUMIN BINDERS
    Publication number: 20200283509
    Abstract: The present invention relates to amino acid sequences binding to serum albumin. In particular, the present invention relates to improved immunoglobulin single variable domains (also referred to herein as “ISV's” or “ISVD's”), and more in particular improved heavy-chain immunoglobulin single variable domains (also referred to herein as “ISV's” or “ISVD's”) binding to serum albumin, as well as to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise such improved serum albumin binders.
    Type: Application
    Filed: November 17, 2016
    Publication date: September 10, 2020
    Applicant: Ablynx N.V.
    Inventor: Marie-Ange Buyse
  • IMMUNOGLOBULIN VARIABLE DOMAINS
    Publication number: 20200231662
    Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).
    Type: Application
    Filed: November 26, 2019
    Publication date: July 23, 2020
    Applicant: Ablynx N.V.
    Inventors: Marie-Ange Buyse, Carlo Boutton
  • TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
    Publication number: 20200216532
    Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).
    Type: Application
    Filed: March 18, 2020
    Publication date: July 9, 2020
    Applicant: Ablynx N.V.
    Inventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Neotere Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
  • PSEUDOMONAS AERUGINOSA PCRV BINDING SINGLE VARIABLE DOMAIN ANTIBODIES
    Publication number: 20200190217
    Abstract: Polypeptides are provided that are capable of significantly inhibiting and/or neutralizing P. aeruginosa. The polypeptides comprise two or more immunoglobulin single variable domains that are directed against the PcrV protein of P. aeruginosa, wherein the “first” immunoglobulin single variable domain and the “second” immunoglobulin single variable domain have different paratopes.
    Type: Application
    Filed: July 17, 2018
    Publication date: June 18, 2020
    Applicant: Ablynx N.V.
    Inventors: Evelyn De Tavernier, Ann Union, Bruno Dombrecht, Guy Hermans, Erika Morizzo
  • T CELL RECRUITING POLYPEPTIDES CAPABLE OF BINDING CD123 AND TCR ALPHA/BETA
    Publication number: 20200157216
    Abstract: Polypeptides are provided that bind CD123 on a target cell and the constant domain of TCR on a T cell. The polypeptides can be used in methods for treatment of CD123 associated cancers or inflammatory conditions.
    Type: Application
    Filed: November 16, 2017
    Publication date: May 21, 2020
    Applicant: Ablynx N.V.
    Inventors: Diane Van Hoorick, Annelies Roobrouck, Catelijne Stortelers, João Vieira, Edward McGowan